Companies Dominating the Polycystic Kidney Disease Drugs Landscape
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Exelixis, Inc.
- XORTX Therapeutics, Inc.
- AstraZeneca PLC
- Manros Therapeutics
- Regulus Therapeutics Inc.
- Reata Pharmaceuticals, Inc.
- Pano Therapeutics, Inc.
- Taro Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc.
Browse Key Market Insights with Data Illustration:
In the News
-
XORTX Therapeutics Inc. declared the positive outcomes from XRX-OXY-101 (“PK Clinical Trial”). The outcomes showed an increase in oral bioavailability for two versions compared to a control formulation in advance of ADPKD's late-stage phase 3 registration trial.
-
Pano Therapeutics, Inc. has acquired the privately-held NovaTarg Therapeutics, Inc. to strengthen Pano Therapeutic Inc’s drug discovery and development capabilities and enhance its portfolio.
